Skip Navigation

JNCI Journal of the National Cancer Institute 2004 96(13):980-981; doi:10.1093/jnci/djh214
© 2004 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (7)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Wells, S. A.
Right arrow Articles by Nevins, J. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wells, S. A.
Right arrow Articles by Nevins, J. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 Oxford University Press

EDITORIAL

Evolving Strategies for Targeted Cancer Therapy—Past, Present, and Future

Samuel A. Wells, Joseph R. Nevins

Affiliation of authors: Duke University Medical Center, Durham, NC.

Correspondence to: Samuel A. Wells, MD, Duke University Medical Center, P.O. Box 3627, Durham, NC 27710 (e-mail: wells029@surgerytrials.duke.edu)

The first 10% of the full text of this article appears below.

Medullary thyroid carcinoma occurs most often as a sporadic malignancy, although in approximately 30% of cases, it occurs as part of the multiple endocrine neoplasia type 2 (MEN2) syndromes MEN2A and MEN2B or the related disease, familial medullary thyroid carcinoma. These three syndromes, inherited as autosomal dominant traits, are clinically characterized by near complete penetrance but variable expressivity. The thyroid malignancy is present in virtually all patients with MEN2A, MEN2B, and familial medullary thyroid carcinoma, and it is the most common cause of death in affected patients. Medullary thyroid carcinoma cells secrete the hormone calcitonin, and elevated plasma levels of this polypeptide, either basally or following provocation with intravenous calcium and pentagastrin, indicate the presence of . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Mol EndocrinolHome page
A. Cerrato, V. De Falco, and M. Santoro
Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets
J. Mol. Endocrinol., October 1, 2009; 43(4): 143 - 155.
[Abstract] [Full Text] [PDF]

Home page
 Arch SurgHome page
S. Y. Boostrom, C. S. Grant, G. B. Thompson, D. R. Farley, M. L. Richards, T. L. Hoskin, and I. D. Hay
Need for a Revised Staging Consensus in Medullary Thyroid Carcinoma
Arch Surg, July 1, 2009; 144(7): 663 - 669.
[Abstract] [Full Text] [PDF]

Home page
 radtechHome page
A. M SCOTT
Thyroid Cancer in Adults
Radiol. Technol., January 1, 2009; 80(3): 241 - 261.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
F. Carlomagno, S. Anaganti, T. Guida, G. Salvatore, G. Troncone, S. M. Wilhelm, and M. Santoro
BAY 43-9006 inhibition of oncogenic RET mutants.
J Natl Cancer Inst, March 1, 2006; 98(5): 326 - 334.
[Abstract] [Full Text] [PDF]